title: Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults.
abstract: We studied preexisting respiratory syncytial virus (RSV)-specific serum and nasal antibodies and their correlation with infectivity, viral dynamics, and disease severity in a human experimental infection model. Higher preinoculation serum neutralizing antibody titers and nasal immunoglobulin (Ig) A predicted lower infectivity and lower measures of viral replication. However, once individuals were infected, no significant protective effect of preexisting antibodies was seen. Lack of correlation between serum and mucosal antibodies was observed, implying that they are independent co-correlates of protection against RSV infection. We suggest that protection from RSV infection is a function of a complex interplay between mucosal and serum humoral immune responses.
authors.affiliation: Department of Pediatrics, University of Tennessee Health Science Center Le Bonheur Children's Hospital, Memphis, Tennessee Children's Foundation Research Institute, Memphis, Tennessee.
authors.forename: Bindiya
authors.initials: B
authors.lastname: Bagga
authors.affiliation: Alnylam Pharmaceuticals, Cambridge, Massachusetts.
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Cehelsky
authors.affiliation: Alnylam Pharmaceuticals, Cambridge, Massachusetts.
authors.forename: Akshay
authors.initials: A
authors.lastname: Vaishnaw
authors.affiliation: Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, United Kingdom.
authors.forename: Tom
authors.initials: T
authors.lastname: Wilkinson
authors.affiliation: Alnylam Pharmaceuticals, Cambridge, Massachusetts.
authors.forename: Rachel
authors.initials: R
authors.lastname: Meyers
authors.affiliation: Department of Pediatrics, University of Tennessee Health Science Center.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Harrison
authors.affiliation: Department of Pediatrics, University of Tennessee Health Science Center Le Bonheur Children's Hospital, Memphis, Tennessee Children's Foundation Research Institute, Memphis, Tennessee.
authors.forename: Philippa L
authors.initials: PL
authors.lastname: Roddam
authors.affiliation: University of Rochester School of Medical and Dentistry and Rochester General Hospital, New York.
authors.forename: Edward E
authors.initials: EE
authors.lastname: Walsh
authors.affiliation: Department of Pediatrics, University of Tennessee Health Science Center Le Bonheur Children's Hospital, Memphis, Tennessee Children's Foundation Research Institute, Memphis, Tennessee Department of Molecular Sciences, University of Tennessee Health Sciences Center, Memphis.
authors.forename: John P
authors.initials: JP
authors.lastname: DeVincenzo
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis*; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity / Q000276:immunology; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology* / Q000517:prevention & control; D022261:Respiratory Syncytial Virus Vaccines / Q000276:immunology*; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D022261:Respiratory Syncytial Virus Vaccines
keywords: correlates of protection; mucosal antibody responses; respiratory syncytial virus; serum antibody responses; vaccines